Bioventus Inc (BVS) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 63/100GuruFocus · Oct 12, 2026
Comparing Kestra Medical Technologies (NASDAQ:KMTS) & Bioventus (NASDAQ:BVS)Defense World · Oct 12, 2026
Reviewing Bioventus (NASDAQ:BVS) & RxSight (NASDAQ:RXST)Defense World · Oct 6, 2026
Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential SaleSeeking Alpha · Sep 21, 2026
Are Medical Stocks Lagging Bioventus (BVS) This Year?Zacks Investment Research · Aug 24, 2026
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate HikeZacks Investment Research · Aug 20, 2026Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $0.22 | $0.22 | Beat |
| May 6, 2026 | $0.09 | $0.15 | Beat |
| Mar 5, 2026 | $0.22 | $0.24 | Beat |
| Nov 4, 2025 | $0.22 | $0.15 | Miss |
| Aug 6, 2025 | $0.22 | $0.21 | Miss |
| May 6, 2025 | $0.06 | $0.08 | Beat |